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Abstract: Myeloid dendritic cells (mDCs) play a complex role in HIV infection regardless of viral 
replication. The aim of our study was to analyse mDCs in long term antiretroviral therapy (ART)-
suppressed HIV-infected patients. We evaluated the numbers of mDCs and slanDC in the context of 
different degree of CD4+ T cell recovery, persistent T cell activation (as HLA-DR+/CD38+ expression) 
and monocyte-macrophage activation assessed in terms of circulating levels of both sCD14 and 
sCD163. We enrolled 72 aviremic patients under effective ART and 34 healthy donors (HD). Patients 
were divided into two groups on the bases of ΔCD4, indicating the difference between the value of CD4 at the time of 
sampling and CD4 nadir. Higher levels of mDCs and slanDC were found in patients with ∆CD4>200/mmc in comparison 
to HD. In those patients also an increased level of sCD14 was found, whereas sCD163 seemed to be at normal levels. An 
augmentation of activated CD4 T lymphocytes was found, although less pronounced in patients with ΔCD4<200/mmc. In 
conclusion, our findings showed an expansion of mDCs with a shift to inflammatory slanDC that could sustain both 
microbial translocation and HIV latency in CD4 T cells. 
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1. INTRODUCTION 
 HIV infection is characterized by an immune activation 
that results in increased cell turnover, immune system 
exhaustion and progression to AIDS. The general 
contribution of HIV replication is uncertain, because there is 
immune activation found also in patients with undetectable 
viremia [1] and a lack of immune activation in the presence 
of high viral load in simian immunodeficiency virus 
infection [2], suggesting that plasma virus replication is not 
an absolute requirement for systemic immune activation. 
Moreover, low levels of immune activation persist overtime 
also in HIV-infected patients under effective antiretroviral 
therapy (ART) despite CD4 T cells recovery and viral 
suppression [3]. Causes and mechanisms of this chronic 
inflammatory status are poorly understood, but are likely to 
be multifactorial and encompass innate and adaptive immune 
responses, with T-cell- and monocyte/macrophage-
associated markers as well as inflammatory soluble plasma 
molecules being predictive of disease progression [4]. In this 
regard, the analysis of HLA-DR/CD38 expression on T-cells 
and the measurement of circulating levels of soluble CD14 
(sCD14) and CD163 (sCD163) are increasingly being 
recognized as important parameters to assess the degree of 
T-lymphocytes and monocyte/macrophages activation during 
the course of HIV infection [5,6]. 
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 Persistent T and myeloid cell activation are present even 
in patients with successful HIV suppression, and are linked 
to non-AIDS morbidity and mortality [7,8]. In this context 
the contribution of dendritic cells (DCs) in sustaining HIV- 
associated immune activation is not completely understood. 
 DCs participate in the immune dysregulation 
characteristic of chronic HIV infection, through the secretion 
of inflammatory cytokines and interferons, and DCs also 
alter T cell proliferation and differentiation [4]. Myeloid 
(mDCs) and plasmacytoid dendritic cells (pDCs) decrease 
rapidly during the first weeks of HIV infection and their 
circulating levels are only partially restored after the 
beginning of ART, especially for pDCs [9,10]. In addition, a 
low baseline pDCs count predicts virological failure in ART 
treated patients, despite CD4+ T cells recovery [11]. 
 A third subset of DCs was identified in peripheral blood 
using the monoclonal antibody M-DC8, which binds to 6-
sulfo LacNac (slan), a carbohydrate moiety of the P selectin 
glycoprotein ligand 1 (PSGL-1) [12,13]. SlanDC cells seem 
to derive from the pro-inflammatory CD14+CD16+ 
monocytes [14] and to contribute to the pathogenesis of 
chronic inflammatory diseases such as Crohn’s disease, 
rheumatoid arthritis and psoriasis, since they infiltrate the 
inflamed ileal mucosa, skin and synovial tissue [15,16]. 
 Recent data suggest a critical role of mDCs and in 
particular of slanDC in driving immune activation in viremic 
HIV-infected patients [17]. On the other hand, the increased 
microbial translocation with release of LPS and 
inflammatory cytokines could represent one of the major 
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stimuli for mDC generation and activation during HIV 
infection. The high degree of plasticity associated with the 
high capacity of recruitment at tissue-level, frame the mDCs 
and slanDC as potential key effector cells involved in 
inflammatory HIV-mediated disorders. 
 In the present study, we analysed the mDC compartment 
in a cohort of patients who have undetectable HIV viremia 
following long term treatment with ART. In particular, we 
evaluated the numbers of mDCs and slanDC in the context 
of different degree of CD4+ T cell recovery, persistent T cell 
activation (percentage of HLA-DR+/CD38+ double positive 
T Lymphocytes) and monocyte-macrophage activation 
assessed in terms of circulating levels of both sCD14 and 
sCD163. 
2. METHODS 
2.1. Study Population 
 The study was approved by the local ethics committee 
and all the recruited subjects provided a written informed 
consent to participate. 
 The study population was selected from all patients who 
presented consecutively to the Outpatients Clinic of the 
Department of Public Health and Infectious Diseases, 
Sapienza University of Rome. Inclusion criteria were 
patients (i) with at least 2 undetectable (<37copies/ml) 
determinations of HIV-RNA levels in the previous 12 
months, (ii) on a stable ART for at least 2 years and (iii) free 
from any acute infections at the time of blood collection. 
Exclusion criteria were pregnancy, age <18 years, hepatitis B 
and C infection. Based on the selected criteria 72 HIV 
infected subjects were enrolled in the study. Moreover a 
group of 37 healthy donors (HD) was included in the study 
as controls. Demographic, clinical and laboratory data as 
well as therapies were collected for all participants. 
 The CD4+ T lymphocytes count at the time of sampling 
and the CD4 nadir were used to calculate ΔCD4, as the 
difference between the two parameters. According to ΔCD4 
value, patients were divided into two groups: the first with 
56 subjects with ΔCD4>200 cells/mmc and the second one 
with 16 subjects with ΔCD4<200 cells/mmc. The value of 
200 cells/mmc, as a cut-off for ΔCD4, was chosen on the 
basis of studies that have shown a correlation between this 
parameter and the risk of clinical progression of the disease 
[18,19]. 
2.2. Enumeration of DCs 
 To identify the number of DCs subsets was used a whole 
blood assay with a protocol no lyse no wash. This method 
allowed us to quantify the absolute number of cell subsets 
using the MACSQuant Analyser. 50 µl of whole blood were 
stained with a mixture of antibodies following titration: 
CD3-PerCP, CD20-PerCP, CD14-PerCP, CD56-PerCP, 
HLA-DR-APC and M-DC8-FITC (all from Miltenyi Biotec, 
Germany), CD235a-PerCP and CD123-BV (BioLegend, Inc, 
USA), CD11c-PE (BD Biosciences Pharmagen, Italy). After 
30 minute incubation, at room temperature, in the dark, the 
lyse solution was added and, after an additional 10 minute 
incubation, data were acquired using the flow cytometer. 
Before data acquisition began a calibration was performed, 
using MACSQuantTM Calibration Beads (Miltenyi Biotec, 
Germany). Cells were run on a MACS-Quant Analyser and 
analysis was performed using MACSQuantifyTM software 
(Miltenyi Biotec, Germany). Peripheral blood mononuclear 
cells (PBMCs) (R1 gate) were gated in a dot plot of Side 
Scatter Channel (SSC) versus Forward Scatter Channel 
(FSC). CD3, CD20, CD14, CD56 and CD235a (lineage) 
surface markers were used to exclude T and B lymphocytes, 
monocytes, NK cells and erythrocytes, respectively. From 
R1 gate, total DCs were defined as HLA-DR+ Lineage- (R2 
gate). On R2 gate, dendritic cell markers CD123 and CD11c 
were used to define pDCs (R3 gate) and mDC (R4 gate) 
respectively. On mDCs gate we identified slanDC as cells 
M-DC8+ and CD11c+ positive. 
2.3. CD4+ and CD8+ Activation 
 Activation markers of CD4+ and CD8+ T lymphocytes 
were evaluated by staining 50 µl of whole blood with a mix 
of pre-titred monoclonal antibodies containing CD45-
VioBlue, HLA-DR-FITC, CD38-APC, CD8-PerCP and 
CD4-PE (all from Miltenyi Biotec, Germany). After 20 
minute incubation, at room temperature and in the dark, lyse 
solution was added and after additional 10 minute 
incubation, data were acquired using MACS-Quant Analyser 
and then analysed by MACSQuantifyTM software (Miltenyi 
Biotec, Germany). SSC and CD45 were used to identify 
lymphocytes. In lymphocytes, CD4 and CD8 were gated. 
Finally, we gated HLA-DR+/CD38+ double positive CD4+ 
and CD8+ T cells to identify activated lymphocytes. 
2.4. sCD14 and sCD163 Plasma Levels 
 Plasma samples were frozen at -80° until analysed. 
Soluble immune activation markers sCD14 and sCD163 
were measured by ELISA (Quantikine ® ELISA, R&D 
Systems, Inc. Minneapolis, USA), according to 
manufacturer’s instructions. All samples were tested in 
double. 
2.5. Statistics 
 For statistical analysis, SPSS version 20.0 for windows 
(SPSS Inc., Apache Software Foundation, Chicago, Illinois) 
was used. Statistical comparison between groups was done 
using the Kruskal–Wallis test followed by Dunnett’s post 
hoc test to detect differences between all groups. Spearman's 
rank correlation coefficient was calculated to determine 
associations between variables. P value <0.05 was 
considered statistically significant. 
3. RESULTS 
3.1. Demographical, Clinical and Laboratory Findings 
 72 HIV infected subjects (40 males and 32 females) were 
enrolled into the study, with the following characteristics 
(data are expressed as median and ranges): age 51 years (23-
79), CD4 nadir 107/mmc (4-613), actual CD4 550/mmc (92-
1550), estimated years to be living with HIV infection 14 (2-
26). Regarding ART, 26 patients were under a triple 
combination therapy containing a protease inhibitor, 34 
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containing a non nucleoside reverse transcriptase inhibitor 
and 12 containing an integrase inhibitor. The median (range) 
period of continuous HIV viral suppression was 3 years (1-
7). The HD were 37, 18 males and 19 females, with a median 
age of 42 (20-54). 
3.2. Enumeration of mDC and slanDC 
 In all HIV-infected patients, mDC levels were not 
different compared to HD (cells/ml median, range, 
27000/ml, 531-92135 vs 20008/ml, 7760-57900 p=0.09). 
 Stratifying subjects according to ΔCD4, we found that 
the absolute number of mDCs was significantly lower in 
patients with ΔCD4<200 cells/mmc, compared to patients 
with ΔCD4>200 cells/mmc (16750/ml, 1657-42787 vs 
32271/ml, 531-92135; p<0.001). Interestingly, the group of 
ΔCD4> 200 cells/mmc showed a number of mDCs higher 
than HD (32271/ml, 531-92135 vs 20008/ml, 7760-57900 
p=0.01) (Fig. 1A). The median percentage of mDCs, within 
total PBMCs, was higher in patients with ΔCD4>200 
cells/mmc compared to those with ΔCD4<200 cells/mmc 
(0,63% vs 0.3%, p=0.006) and with HD (0,63% vs 0.41%, 
p=0.004). 
 
Fig (1). Enumeration of myeloid DC and slanDC in the study 
population according to ΔCD4. DCs were measured using a 
whole blood assay no lyse no wash. Box Plots represent circulating 
mDCs (A), M-DC8
+
 (B) in patients with ΔCD4>200 cells/mmc and 
ΔCD4<200 cells/mmc in comparison to healthy donors. Boxes 
show 25th, 50th (median) and 75
th
 percentile and wiskers 10
th
 and 
90th percentile. Dots represent outlying values. Statistical 
significance was analyzed by using Kruskal-Wallis test. HD: 
healthy donors. 
 In a subgroup of 35 patients we evaluated slanDCs, that 
were increased in patients with ΔCD4>200 compare to HD 
and in patients with ΔCD4< 200 (15050/ml, 3200-42600 vs 
8830/ml, 1300-30900 p=0.01 and 5600/ml, 840-20700 
p=0.01) (Fig. 1B). The median percentage of slanDCs was 
higher in patients with ΔCD4>200 cells/mmc compared to 
those with ΔCD4<200 cells/mmc (0,24% vs 0.08%, p=0.02) 
and to HD (0,24% vs 0.12%, p=0.01). 
Moreover, we defined the proportion of mDC coexpressing 
M-DC8 markers, computing the percentage of slanDC and 
M-DC8 negative cells on mDC. We found an increasing 
trend of slanDCs in patients with ΔCD4>200 (49%, 9-75) in 
comparison with HD (39%, 5-93) and subjects with ΔCD4< 
200 (34%, 8-57) (Fig.  2A). 
 No differences were observed in pDCs count in patients 
and HD (6040, 640-20826 vs 6222, 3100-14900, p= 0.8), 
even stratifying according to ΔCD4 (ΔCD4<200 vs 
ΔCD4>200, 4735, 640-19115 vs 6579, 1120-20826) and 
between HD and ΔCD4< and >200 (p>0.05). The median 
percentage of pDCs, did not show differences between 
groups. 
3.3. CD8+ and CD4+ Immune Activation 
 All HIV positive patients showed a significant increase in 
HLA-DR and CD38 expression on CD4+ cells compared to 
HD (1.8%, vs 1.04%, p=0.003). The group of patients with 
ΔCD4<200 showed the highest level (2.37% vs 1.04%, 
p=0.003), although even in patients with ΔCD4>200, a 
higher percentage of CD38 and HLA-DR coexpression 
compared to HD was observed (1.76%, vs 1.04%, p=0.01) 
(Fig. 3). There were no significant differences in the 
percentages of HLA-DR+/CD38+ CD8+ T cells between 
HIV patients and HD (0.8% vs 1.24%, p=0.6), neither 
according to CD4 recovery (ΔCD4>200 vs ΔCD4<200: 
0.7%, vs 1.67%, p=0.6). 
3.4. sCD14 and sCD163 Plasma Levels 
 sCD163 levels were significantly higher in all HIV 
subjects compared to HD (574 ng/ml, 58-2364 vs 377 ng/ml, 
215-1026; p=0.03), sCD163 was significantly increased in 
patients with ΔCD4<200, compared with subjects with 
ΔCD4>200 and HD (853 ng/ml,150-2310 vs 548 ng/ml, 58-
2364 and vs 377 ng/ml, 215-1026; p= 0.03 and p=0.01) (Fig. 
4A). 
 sCD14 levels were higher in HIV patients compare to 
HD (1989 ng/ml, 210-4799 vs 855 ng/ml, 290-2467; 
p=0.005), and subjects with ΔCD4>200 had even a higher 
level of sCD14 in comparison with patients with ΔCD4<200 
(2139 ng/ml, 210-4799 vs 970 ng/ml, 510-2779, p=0.04) 
(Fig. 4B). 
3.5. Correlation Analysis 
 We observed a positive correlation between the absolute 
number of mDCs and slanDC (r=0.773, p<0.001), between 
ΔCD4 and slanDCs (r=0.413, p=0.02) and pDCs (r=0.379, 
p=0.001) and between HLA-DR+/CD38+ CD4+ and HLA-
DR+/CD38+ CD8+ (r=0.37, p=0.006). 
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Fig (2). Frequency of slanDC (M-DC8
+
) cells in mDC gate. Pies represent the percentage of M-DC8
neg
 versus slanDC (M-DC8
+
) in 
healthy donors and patients with ΔCD4>200 cells/mmc and ΔCD4<200 cells/mmc (A). Fig. (2B) shows three representative analysis from an 
healthy donor (left panel), a subject with ΔCD4>200 (middle panel) and a subject with ΔCD4<200 (right panel). Dot plots identify mDC, 
slanDC, and slanDCs within mDCs gate in a cytofluorimetric backgating analysis using different colour. 
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 Regarding sCD163 and pDCs we found a negative 
correlation (r=-0.241, p=0.04). No other important 
correlations were found. 
 Concerning clinical parameters, we found a positive 
correlation between the value of sCD14 and the years of HIV 
infection (r=0.3, p=0.01) and between sCD163 and age 
(r=0.305, p=0.01). No other correlations were found (Tables 
1 and 2). 
 
Fig. (3). HLA-DR+/CD38
+
 CD4
+
 T cells according to ΔCD4. Box 
plots represent the percentage of HLA-DR
+
/CD38
+
 CD4
+
 T cells in 
patients and healthy donors. Activation of CD4
+
T lymphocytes was 
analyzed by using a whole blood assay no lyse no wash. Boxes 
show 25th, 50th (median) and 75
th
 percentile and wiskers 10
th
 and 
90th percentile. Dots represent outlying values. Statistical 
significance was analyzed by using Kruskal-Wallis test. HD: 
healthy donors. 
4. DISCUSSION 
 DCs are the most efficient antigen-presenting cells 
(APCs), expressing high levels of major histo-compatibility 
complex (MHC) class II molecules, with the ability to 
regulate both innate and adaptive immune response towards 
pathogens [20]. They have the capacity to localize to various 
tissues/organs, and migrate to lymphoid tissues after antigen 
acquisition, where they secrete cytokines and initiate 
immune response [21]. 
 There are two major subsets of DCs, mDCs and pDCs, 
which differentiate from precursors found in the bone 
marrow and migrate to the periphery as immature cells. The 
effects of HIV infection on pDC have been widely 
investigated and previous data indicate that this DC subset is 
persistently impaired in number and function despite 
effective ART. On the other hand, there has been a renewed 
interest in the mDC subset that seems to play a complex role 
in HIV infection. mDC are involved in multiple processes of 
the immune response including the stimulation, maintenance 
and control of both immunity and inflammation. In addition, 
mDC cells are able to act as immune sentinels to detect and 
regulate aberrant immune activation, induce tolerance, 
avoiding autoimmune diseases [21]. A cytotoxic function 
was also attributed to mDC in both neoplastic [22] and other 
viral infections beyond HIV, such as Ebola and measles 
[23,24]. 
 
Fig. (4). sCD14 and sCD163 plasma levels. Levels of soluble 
immune activation markers, sCD14 and sCD163, in plasma were 
tested by ELISA kit. Dot plots represent the ng/ml of soluble 
markers in patients and control. Lines indicate the median value. 
Statistical significance was analyzed by using the Kruskal-Wallis 
test. HD: healthy donors. 
 In this study we evaluated the role of mDCs and in 
particular of slanDCs, in a cohort of HIV-infected patients 
undergoing effective ART. We found that HIV-infected 
patients with persistent undetectable viremia following long-
term ART treatment had increased circulating levels of 
mDCs if compared to healthy donors. Interestingly, the most 
significant increase of these cells was found especially in 
subjects with a better CD4 recovery (>200 cell/mmc) 
suggesting a concomitant recovery of both arms of cellular 
immune system: the innate and the adaptive ones. However, 
comparing mDC level of patients with ΔCD4>200 to HD we 
have observed not just a recovery but a truly mDC 
expansion. It remains to be clarified the role of this finding 
in the context of HIV pathogenesis, considering the multiple 
functions of mDCs. In fact, mDCs are pivotal players in HIV 
infection, promoting transmission and spread and at the same 
time are critical for recognizing HIV and initiating immune 
responses to fight infection [25]. Considering these 
functional features, it can be assumed that in HIV 
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pathogenesis, in which the disease progression is driven by 
high degree of immune activation and inflammation, mDCs 
may have a significant role [26]. Increase in the number and 
in the differentiation degree of CD11c+ dendritic cells was 
observed also in several autoimmune [27] and chronic 
inflammatory diseases [28,29] suggesting a role of these 
cells in sustaining inflammation in non microbial diseases. 
Some authors suggest that mDCs elevation was sustained by 
microbial translocation or asymptomatic low grade 
infections that act as a trigger to mDC differentiation and 
recruitment [30]. Enumeration of mDC in blood has been 
proposed as a predictive tool for monitoring chronic 
inflammatory disease because the augmentation in blood 
seems to precede the tissue involvement [31]. 
 Recently, a significant increase in the number of 
circulating slanDC cells, a major myeloid-derived 
proinflammatory subpopulation of human blood DCs, has 
been described in HIV viremic patients compared to both 
healthy donors and virologically suppressed ART-treated 
patients [17,32]. Moreover, slanDCs from viremic ART 
naïve patients are involved in Tumor Necrosis Factor (TNF) 
-α production in response to LPS, suggesting a pivotal role in 
the pathogenesis of deleterious immune activation [17]. In a 
subset of our ART-suppressed HIV-infected patients we also 
evaluated slanDCs. We observed that the percentage of 
slanDCs was significantly higher in subjects with 
ΔCD4>200. Conversely, in subjects with ΔCD4<200 we 
found a lower absolute number of mDCs with a low 
percentage of slanDC, although the small number of patients 
in this group could represent a limitation. As expected, 
slanDCs positively correlated with mDCs and ∆CD4; 
moreover a positive correlation with pDCs was found. A 
higher percentage of slanDC, usually known as 
inflammatory DC, can represent the potential dangerous face 
of the observed myeloid expansion [16,17,33,34]. 
 In the present study, the analysis of DC subsets was done 
according to the CD4+ T cell recovery, but also in the 
context of persistent T cell and monocytes/macrophages 
activation. Concerning T cells compartment, we observed 
higher levels of the immune activation markers HLA-DR 
and CD38 on CD4+ T cells, indicating persist latent HIV 
infection of these cells. Several studies showed an increased 
frequency of HLA-DR+/CD38+ CD4+ and/or CD8+ T 
lymphocytes in subjects with a persistent viral suppression 
Table 1. Spearman’s correlations between subpopulations of dendritic cells, activated T lymphocytes and soluble factors. 
 
  mDC slanDC pDC CD4+ DR+/38+ CD8+ DR+/38+ sCD14 sCD163 
mDC 
R  0.773 0.198 -0.166 -0.067 0.052 -0.0007 
p  <0.001 0.1 0.2 0.6 0.7 0.9 
slanDC 
R   0.255 0.029 -0.056 0.236 -0.006 
p   0.1 0.9 0.8 0.2 0.9 
pDC 
R    0.201 -0.242 0.162 -0.241 
p    0.1 0.08 0.2 0.04 
CD4+/ DR+/38+ 
R     0.37 0.041 0.234 
p     0.006 0.8 0.09 
CD8+/ DR+/38+ 
R      -0.465 0.239 
p      0.01 0.08 
sCD14 
R       0.21 
p       0.08 
 
Table 2. Spearman’s correlations between subpopulations of dendritic cells, activated T lymphocytes soluble factors and clinical 
parameters. 
 
  mDC slanDC pDC CD4+ DR+/38+ CD8+ DR+/38+ sCD14 sCD163 
ΔCD4 
R 0.28 0.413 0.379 -0.164 -0.298 0.096 -0.258 
p 0.2 0.02 0.001 0.2 0.02 0.4 0.03 
Years of HIV 
R -0.007 0.015 0.154 0.161 -0.113 0.3 0.133 
p 0.9 0.9 0.2 0.2 0.4 0.01 0.3 
Age 
R 0.034 0.068 -0.067 -0.011 -0.05 0.145 0.305 
p 0.7 0.7 0.6 0.9 0.7 0.2 0.01 
CD4 Nadir 
R -0.169 -0.013 0.18 -0.111 0.058 0.161 0.072 
p 0.1 0.9 0.1 0.4 0.7 0.2 0.5 
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[6,35]. Older age and low CD4 count (and as a consequence 
lower ΔCD4) could be the leading factors for immune 
activation in our cohort of patients. Moreover in an in vitro 
model of cell to cell contact, resting memory CD4+ T cells 
seem to be latently infected by HIV only in the presence of 
mDCs [36]. Thus the high amount of mDCs found in long 
term ART aviremic patients may facilitate residual ongoing 
infection of resting T cells and supply the HIV reservoir in 
the tissues [36]. However, mDCs themselves can serve as 
reservoir for HIV, in addition to spread the virus [37]. We 
did not find significant differences in CD8+ T lymphocyte 
activation between HIV infected subjects and uninfected 
controls, but we observed a direct correlation between the 
levels of CD4 and CD8 activation. Moreover, the CD8 
immune activation was inversely correlated to ΔCD4. 
 In order to assess whether the expansion of mDC and 
slanDC was associated to the residual monocyte/macrophage 
innate immune activation, we measured circulating levels of 
sCD14 and sCD163. Both sCD14 and sCD163, were found 
to be increased in patients with both AIDS and non-AIDS 
related diseases [7,8,38,39]. sCD14 exerts an inflammatory 
effect and is produced mainly by monocytes, whereas 
sCD163 has an anti-inflammatory modulatory effect and is 
released by monocytes/macrophages and other tissue cells. A 
sCD14-dependent pathway has been demonstrated in the 
LPS activation of DCs, especially with low levels of LPS 
and has been found in aviremic subjects [40]. In aviremic 
ART treated subject a persistent low level of LPS was 
described suggesting that in this population plasma sCD14 is 
fundamental to maintain residual immune activation [40]. 
Moreover, a subpopulation of circulating mDC expresses 
CD163, together with CD91, and is expanded in HIV-
infected patients showing an immunostimulatory role besides 
its effect in hemoglobin scavenging and anti-inflammation 
[41]. 
 In our study we found an increase in sCD14 plasma 
levels, more pronounced in patients with a good CD4 
recovery (∆CD4>200) suggesting persistent monocyte 
activation together with mDC increase also in aviremic 
subjects. sCD14 correlated with the years of HIV infection 
independently from the duration of therapy. The increase of 
sCD14, in part due to microbial translocation, could act as a 
stimulus for mDCs and slanDC production and expansion 
from circulating monocytes. Concomitantly this myeloid 
expansion could sustain the persistent bowel mucosa 
damage. In fact slanDCs are found in abundance in inflamed 
mucosal tissues [33] and they produce large amounts of 
TNF-α, which have an important role in the intestinal 
epithelial cell destruction, leading to LPS translocation [42] 
by setting up a vicious circle. Conversely in our study, we 
did not find a significant correlation between sCD14 level 
and mDC or slanDC number, indicating that other factors 
could be important in the myeloid expansion. 
 The other soluble factor related to myeloid activation, 
sCD163, seems to have an important role as a regulator 
factor with a quenching role in terminating inflammation, 
especially at tissue macrophage level [43]. In fact, together 
with its physiological role, which is the inhibition of cellular 
growth after sequestering extracellular haemoglobin iron 
[44], sCD163 inhibits the activation and proliferation of T 
lymphocytes by limiting the activation of the inflammatory 
response [43]. 
 In our study sCD163 plasma levels were persistently 
increased in ART patients with ∆CD4<200 suggesting a 
potential immunosuppressive role on CD4+ T cells. As 
already observed [45,46], sCD163 levels correlated with age 
of patients, suggesting the inability of CD4 recovery in 
normalizing sCD163 in older HIV subjects. sCD163 levels 
were not related to mDC and slanDC cells, but were 
inversely related to pDCs that in our cohort showed a full 
recovery. 
 A limitation of our study is the lack of monocyte 
analysis, however a recent study showed a persistent 
alteration of CD16+ monocytes in spite of sCD163 normal 
levels under ART [8]. Besides we did not evaluate soluble 
plasma markers strictly related with DCs (such as TNF-α, 
IFN-α, IL-12, GM-CSF) since they are produced in a limited 
amount in plasma from ART treated subjects [17, 47-48]. Ex 
vivo stimulation with an intracellular assay should be 
performed to better characterize DCs functionality. 
 In conclusion HIV-infected people, who have a persistent 
viral suppression and good CD4 recovery after long term 
ART, exhibits a large expansion of mDCs associated with a 
higher proportion of M-DC8 expression, augmentation of 
sCD14 and CD4 T cells activation despite a normalization of 
pDC count, CD8 activation and sCD163 levels. The 
persistence of microbial translocation and immune activation 
could represent a good environment for the generation of 
slanDCs and mDCs from monocytes in long term aviremic 
ART treated patients. On the other hand, this myeloid 
expansion could sustain both microbial translocation at 
bowel mucosa level and HIV latency in long lived CD4+ T 
cells creating a close and vicious circle. A clinical long term 
follow up of HIV patients with mDC expansion is needed to 
understand if this increase is associated with a higher risk of 
non AIDS events, considering the proinflamatory effect of 
mDC at tissue level. 
 Studies that contribute to an overall understanding of the 
potentially detrimental roles of mDCs during viremic or 
aviremic HIV infection should be strongly encouraged in 
order to assess the clinical consequence and possible 
therapeutic approaches. 
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